

ESF-UB Conference in Biomedicine

Pharmacogenetics and Pharmacogenomics: Adverse Drug Reactions

St Feliu de Guixols, Spain, 27 June – 2 July 2008

www.esf.org/conferences/08269

LIST OF POSTERS Session 1, Saturday 28 June

1	Al Barmawi	Al Bader	<i>Inappropriate drug prescribing in patients with chronic liver disease</i>
2	Al-Serri	Ahmad	<i>The mitochondrial superoxide dismutase 2 (SOD2) targeting sequence polymorphism is associated with fibrotic non-alcoholic fatty liver disease: consistent evidence from case-control and intra-familial allelic association studies</i>
3	Angelini	Sabrina	<i>SNPs analysis to predict response to Imatinib in Chronic myeloid leukemia patients.</i>
4	Barratt	Daniel	<i>Pharmacogenetics of ABCB1 in high dose Methadone maintenance treatment</i>
5	Begdullayev	Almas	<i>Pharmacogenetics of Warfarin–Cytochrome Cyp2c9 and vitamin K epoxide reductase gene polymorphisms in Kazakh population</i>
6	Bozina	Nada	<i>Azathioprine-induced allergic hepatitis associated with thiopurine methyltransferase (TPMT) genotype; case report</i>
7	Aguilera	Margarita	<i>Pharmacogenetics knowledge enlargement for translation to clinical services in the University Hospital Virgen de las Nieves (Granada-Spain)</i>
8	Aguilera Chemello	Margarita Clarice	<i>Pharmacogenetic applications and pharmacotherapy follow-up in patients with Rheumatoid Arthritis</i>
9	Chemello	Clarice	<i>Pharmacotherapy follow-up and pharmacogenetics protocol development for patients with secondary hyperparathyroidism in chronic kidney disease</i>
10	Coller	Janet	<i>Association between genetic variability of pro-inflammatory cytokines and opioid dependence treatment with Methadone</i>
11	Daly	Ann	<i>Genetic Variants Of Hepatic Transporters And Susceptibility To Drug Induced Liver Injury</i>

ESF-UB Conference in Biomedicine

Pharmacogenetics and Pharmacogenomics: Adverse Drug

Reactions St Feliu de Guixols, Spain, 27 June – 2 July 2008

www.esf.org/conferences/08269

LIST OF POSTERS Session 1, Saturday 28 June

12	D'esposito	Fabrizio	<i>Cytochrome P450 3A4-dependent biotransformation of the anticancer agent irinotecan is impaired in chronic liver disease</i>
13	Fakhoury	May	<i>GENDRUG Network : Pharmacogenetics and Adverse Drug Reactions</i>
14	Fifere	Adrian	<i>In vitro and in vivo pharmacological studies of the flucytosine:cyclodextrin inclusion complexes.</i>
15	George	Peter	<i>Mutation analysis in patients with severe 5 FU toxicity</i>
16	Gunes	Arzu	<i>Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine and clozapine</i>
17	Hughes	Dyfrig	<i>Evaluating the cost-effectiveness of pre-prescription pharmacogenetic testing for irinotecan</i>
18	Hughes	Dyfrig	<i>Population Pharmacokinetic analysis of S-warfarin</i>
19	Hughes	Dyfrig	<i>Cost analysis of warfarin therapy</i>
20	Janha	Ramatoulie	<i>Effects of genetic variation at the chromosome 10 CYP2C locus on pharmacokinetics of Chlorcycloguanil in Gambians</i>
21	Jorgensen	Andrea	<i>Effect of CYP4F2 genetic polymorphisms on clinical outcomes in patients initiated on warfarin therapy: a prospective cohort study</i>